Your session is about to expire
← Back to Search
Immunotherapy for Cancer
Study Summary
This trial is testing a new immunotherapy drug for people with advanced cancer who have progressed on standard of care therapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 1274 Patients • NCT02220894Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't taken steroids or immunosuppressants in the last 7 days.I haven't had cancer treatment or still have side effects from the last one within the past 2 weeks.I have or had lung inflammation that needed steroids.I haven't had cancer in the last 2 years, except for certain skin cancers or cancers that were completely removed.You have a severe allergic reaction to pembrolizumab or any of its ingredients.I haven't had cancer treatment with monoclonal antibodies in the last 4 weeks.I have not received a live vaccine in the last 30 days.My cancer is confirmed by lab tests and is an advanced solid tumor.My cancer has worsened or I can't tolerate my current treatment.I can provide a sample of my tumor for the study.Your disease can be seen and measured on a medical scan.My organs are working well.I have not been in a clinical trial for a new treatment or device within the last 4 weeks.I agree to use birth control and not donate or store my eggs for 120 days after my last dose.I have not been in a study or taken drugs targeting immune system checkpoints.I have an active Hepatitis B or C infection.I have an active tuberculosis infection.I have active brain metastases or cancer in the lining of my brain.I have received an organ or tissue transplant from another person.I am currently being treated for an infection.You are expected to live for at least 3 more months.I have been diagnosed with a specific brain tumor in the brain stem.I am fully active or restricted in physically strenuous activity but can do light work.I have been diagnosed with HIV.I have been treated for an autoimmune disease in the last 2 years.
- Group 1: Pembrolizumab 400 mg
- Group 2: Pembrolizumab 200 mg
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In how many different medical facilities is this research project being conducted currently?
"Currently, this trial is open to recruitment at Call for Information (Investigational Site 0005) in Rockville, Massachusetts, Call for Information (Investigational Site 0207) in Boston, New jersey, and Call for Information (Investigational Site 0008) in New Brunswick, California. There are 11 other potential locations where this study could be conducted."
Are patients being enrolled in this experiment right now?
"The study, which was originally posted on December 18th, 2015 is currently looking for participants. The listing was most recently updated on October 21st, 2020."
Has pembrolizumab completed the necessary steps for FDA approval?
"Pembrolizumab's safety was rated a 2 because, while there is data indicating it is safe, there is no evidence that the medication is effective."
What are the common conditions that pembrolizumab helps to alleviate?
"Pembrolizumab is most commonly used to treat various forms of cancer. However, it can also be effective in combination with other treatments for conditions like unresectable melanoma, microsatellite instability high, and disease progression after chemotherapy."
Are there other pembrolizumab clinical trials that we can compare this one to?
"Pembrolizumab is being researched in 122 phase 3 clinical trials, with 1000 studies currently underway. The majority of these research projects are based in Houston, Texas; however, there are 36030 locations worldwide conducting pembrolizumab clinical trials."
Share this study with friends
Copy Link
Messenger